Embecta (Nasdaq:EMBC) announced today that it held a grand opening ceremony at its new global headquarters in New Jersey. The BD Diabetes business spinoff opened its new headquarters at 300 Kimball Drive, Suite 300, in Parsippany, New Jersey. The site houses members of the Embecta leadership team, global support functions and North American commercial organization. […]
embecta
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
Embecta stock slides on mixed Q4 results
Embecta (Nasdaq:EMBC) shares dipped today on fourth-quarter results that came in mixed compared to the consensus forecast. EEMBC shares fell more than 12% to $29.73 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 4%. The Parsippany, New Jersey-based company posted losses […]
Analysts remain neutral on Embecta, await insulin patch pump developments
BTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company’s fourth-quarter earnings report next week. Embecta, the BD diabetes spinoff, reports its fourth-quarter earnings on Tuesday, Dec. 20. Analysts Marie Thibault and Sam Eiber also expect 2023 guidance to come from management then. The analysts mainly expect the patch pump market to […]
Here’s what diabetes tech companies are doing for National Diabetes Awareness Month
As we enter November, we enter National Diabetes Awareness Month. A number of diabetes technology developers plan to mark that in a special way. Dexcom (Nasdaq:DXCM), Insulet (Nasdaq:PODD) and Embecta (Nasdaq:EMBC) all announced their plans to celebrate. Last year, a handful of companies marked the month — which includes World Diabetes Day (Nov. 14) — […]
Analysts see multi-year transition to growth for Embecta
Embecta (Nasdaq:EMBC), the BD diabetes business spinoff, may take a few years to move into a growth phase, analysts say. BTIG analysts Marie Thibault and Sam Eiber wrote a report labeling Embecta as a “Neutral” option on the market. BD initially announced it would spin off its diabetes business in 2021, finally completing the move […]
Embecta stock soars on first full-quarter results after BD spinoff
Embecta (Nasdaq: EMBC) today posted third-quarter results today for the first time as a BD (NYSE: BDX) spinoff, beating the consensus forecast on Wall Street. The Parsippany, New Jersey-based diabetes technology company reported profits of $62.4 million, or $1.08 per share, on sales of $291.1 million for the three months ended June 30. RELATED: How […]
How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD
Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to […]
BD completes spinoff of Embecta diabetes company
BD (NYSE:BDX) announced today that the planned spinoff of its diabetes business — named Embecta (Nasdaq:EMBC)— has been made official. Franklin Lakes, New Jersey-based BD announced its intention to spinoff the diabetes business in May 2021. Near the end of 2021, it unveiled the soon-to-be independent, publicly-traded company’s name as “Embecta,” with plans to complete the spinoff during […]
